Selinexor Patent Expiration
Selinexor is Used for treating relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Multiple Myeloma in adults. It was first introduced by Karyopharm Therapeutics Inc
Selinexor Patents
Given below is the list of patents protecting Selinexor, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Xpovio | US10519139 | Polymorphs of Selinexor | Aug 14, 2035 | Karyopharm Theraps |
| Xpovio | US11746102 | Polymorphs of selinexor | Aug 14, 2035 | Karyopharm Theraps |
| Xpovio | US11753401 | Polymorphs of Selinexor | Aug 14, 2035 | Karyopharm Theraps |
| Xpovio | US11807629 | Polymorphs of Selinexor | Aug 14, 2035 | Karyopharm Theraps |
| Xpovio | US8999996 | Hydrazide containing nuclear transport modulators and uses thereof | Jul 03, 2033 | Karyopharm Theraps |
| Xpovio | US10544108 | Hydrazide containing nuclear transport modulators and uses thereof | Jul 26, 2032 | Karyopharm Theraps |
| Xpovio | US11034660 | Hydrazide containing nuclear transport modulators and uses thereof | Jul 26, 2032 | Karyopharm Theraps |
| Xpovio | US11787771 | Hydrazide containing nuclear transport modulators and uses thereof | Jul 26, 2032 | Karyopharm Theraps |
| Xpovio | US12291508 | Hydrazide containing nuclear transport modulators and uses thereof | Jul 26, 2032 | Karyopharm Theraps |
| Xpovio | US9079865 | Hydrazide containing nuclear transport modulators and uses thereof | Jul 26, 2032 | Karyopharm Theraps |
| Xpovio | US9714226 | Hydrazide containing nuclear transport modulators and uses thereof | Jul 26, 2032 | Karyopharm Theraps |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Selinexor's patents.
Latest Legal Activities on Selinexor's Patents
Given below is the list recent legal activities going on the following patents of Selinexor.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 Apr, 2025 | US9714226 |
| 7.5 yr surcharge - late pmt w/in 6 mo, Large Entity | 11 Apr, 2025 | US9714226 |
| Maintenance Fee Reminder Mailed | 17 Mar, 2025 | US9714226 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 16 Dec, 2024 | US11034660 |
| Recordation of Patent Grant Mailed Critical
| 07 Nov, 2023 | US11807629 |
| Patent Issue Date Used in PTA Calculation Critical
| 07 Nov, 2023 | US11807629 |
| Mail Patent eGrant Notification | 07 Nov, 2023 | US11807629 |
| Email Notification Critical
| 07 Nov, 2023 | US11807629 |
| Patent eGrant Notification | 07 Nov, 2023 | US11807629 |
| Recordation of Patent eGrant | 07 Nov, 2023 | US11807629 |
Selinexor's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Selinexor:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
